PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15585641-0	2004	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.	Tamoxifen	37-46	AKT serine/threonine kinase 1	Homo sapiens	93-96	
15585641-6	2004	This study evaluated the efficacy of mTOR inhibition in the treatment of tamoxifen-resistant breast carcinoma characterized by high Akt activity.	Tamoxifen	73-82	AKT serine/threonine kinase 1	Homo sapiens	132-135	
15585641-7	2004	We found that MCF-7 breast cancer cell lines expressing a constitutively active Akt are able to proliferate under reduced estrogen conditions and are resistant to the growth inhibitory effects of tamoxifen, both in vitro as well as in vivo in xenograft models.	Tamoxifen	196-205	AKT serine/threonine kinase 1	Homo sapiens	80-83	
15585641-10	2004	These data corroborate prior findings indicating that Akt activation induces resistance to tamoxifen in breast cancer cells.	Tamoxifen	91-100	AKT serine/threonine kinase 1	Homo sapiens	54-57	
15585641-11	2004	Importantly, these data indicate a novel mechanism for tamoxifen resistance and suggest that blockage of the phosphatidylinositol 3"-kinase/Akt signaling pathway by mTOR inhibition effectively restores the susceptibility of these cells to tamoxifen.	Tamoxifen	55-64	AKT serine/threonine kinase 1	Homo sapiens	140-143	
15585641-11	2004	Importantly, these data indicate a novel mechanism for tamoxifen resistance and suggest that blockage of the phosphatidylinositol 3"-kinase/Akt signaling pathway by mTOR inhibition effectively restores the susceptibility of these cells to tamoxifen.	Tamoxifen	239-248	AKT serine/threonine kinase 1	Homo sapiens	140-143